• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

组织因子途径抑制剂用于预测高危女性胎盘介导的不良妊娠结局：血管生成预测研究。

Tissue factor pathway inhibitor for prediction of placenta-mediated adverse pregnancy outcomes in high-risk women: AngioPred study.

作者信息

Di Bartolomeo Aurélie, Chauleur Céline, Gris Jean-Christophe, Chapelle Céline, Noblot Edouard, Laporte Silvy, Raia-Barjat Tiphaine

机构信息

Department of Gynaecology and Obstetrics, University Hospital, Saint Etienne, France.

INSERM UMR 1059, Saint Etienne University Jean Monnet, Saint Etienne, France.

出版信息

PLoS One. 2017 Mar 22;12(3):e0173596. doi: 10.1371/journal.pone.0173596. eCollection 2017.

DOI:10.1371/journal.pone.0173596
PMID:28328938
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5362074/
Abstract

OBJECTIVE

The study aimed to evaluate if the rate of tissue factor pathway inhibitor during pregnancy and following delivery could be a predictive factor for placenta-mediated adverse pregnancy outcomes in high-risk women.

METHODS

This was a prospective multicentre cohort study of 200 patients at a high risk of occurrence or recurrence of placenta-mediated adverse pregnancy outcomes conducted between June 2008 and October 2010. Measurements of tissue factor pathway inhibitor resistance (normalized ratio) and tissue factor pathway inhibitor activity were performed for the last 72 patients at 20, 24, 28, 32, and 36 weeks of gestation and during the postpartum period.

RESULTS

Overall, 15 patients presented a placenta-mediated adverse pregnancy outcome. There was no difference in normalized tissue factor pathway inhibitor ratios between patients with and without placenta-mediated adverse pregnancy outcomes during pregnancy and in the post-partum period. Patients with placenta-mediated adverse pregnancy outcomes had tissue factor pathway inhibitor activity rates that were significantly higher than those in patients without at as early as 24 weeks of gestation. The same results were observed following delivery.

CONCLUSION

Among high-risk women, the tissue factor pathway inhibitor activity of patients with gestational vascular complications is higher than that in other patients. Hence, these markers could augment a screening strategy that includes an analysis of angiogenic factors as well as clinical and ultrasound imaging with Doppler measurement of the uterine arteries.

摘要

目的

本研究旨在评估孕期及产后组织因子途径抑制物的水平是否可作为高危女性胎盘介导的不良妊娠结局的预测因素。

方法

这是一项前瞻性多中心队列研究，于2008年6月至2010年10月对200例有胎盘介导的不良妊娠结局发生或复发风险的高危患者进行研究。对最后72例患者在妊娠20、24、28、32和36周以及产后期间进行组织因子途径抑制物抵抗（标准化比值）和组织因子途径抑制物活性的测量。

结果

总体而言，15例患者出现了胎盘介导的不良妊娠结局。在孕期和产后，有胎盘介导的不良妊娠结局的患者与无该结局的患者之间，组织因子途径抑制物标准化比值无差异。有胎盘介导的不良妊娠结局的患者，早在妊娠24周时其组织因子途径抑制物活性率就显著高于无该结局的患者。产后也观察到了相同的结果。

结论

在高危女性中，有妊娠血管并发症的患者的组织因子途径抑制物活性高于其他患者。因此，这些标志物可完善一种筛查策略，该策略包括分析血管生成因子以及结合子宫动脉多普勒测量的临床和超声成像。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a427/5362074/719151e8032e/pone.0173596.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a427/5362074/5ce49903dcd5/pone.0173596.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a427/5362074/e71af777b6d0/pone.0173596.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a427/5362074/719151e8032e/pone.0173596.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a427/5362074/5ce49903dcd5/pone.0173596.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a427/5362074/e71af777b6d0/pone.0173596.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a427/5362074/719151e8032e/pone.0173596.g003.jpg

相似文献

1
Tissue factor pathway inhibitor for prediction of placenta-mediated adverse pregnancy outcomes in high-risk women: AngioPred study.组织因子途径抑制剂用于预测高危女性胎盘介导的不良妊娠结局：血管生成预测研究。
PLoS One. 2017 Mar 22;12(3):e0173596. doi: 10.1371/journal.pone.0173596. eCollection 2017.
2
Angiogenic factors for prediction of preeclampsia and intrauterine growth restriction onset in high-risk women: AngioPred study.预测高危女性子痫前期和胎儿生长受限发病的血管生成因子：血管生成预测研究
J Matern Fetal Neonatal Med. 2019 Jan;32(2):248-257. doi: 10.1080/14767058.2017.1378325. Epub 2017 Sep 22.
3
Mid-trimester uterine artery Doppler screening as a predictor of adverse pregnancy outcome in high-risk women.孕中期子宫动脉多普勒超声筛查作为高危孕妇不良妊娠结局的预测指标
Ultrasound Obstet Gynecol. 2000 Jan;15(1):7-12. doi: 10.1046/j.1469-0705.2000.00014.x.
4
Doppler ultrasound of the uterine artery in the prediction of severe complications during low-risk pregnancies.子宫动脉多普勒超声在预测低风险妊娠严重并发症中的应用
Arch Gynecol Obstet. 2005 Jan;271(1):46-52. doi: 10.1007/s00404-004-0646-6. Epub 2004 Jun 8.
5
Doppler assessment of the uterine and uteroplacental circulation in the second trimester in pregnancies at high risk for pre-eclampsia and/or intrauterine growth retardation: comparison and correlation between different Doppler parameters.子痫前期和/或胎儿生长受限高危妊娠中期子宫及子宫胎盘循环的多普勒评估：不同多普勒参数之间的比较与相关性
Ultrasound Obstet Gynecol. 1997 May;9(5):330-8. doi: 10.1046/j.1469-0705.1997.09050330.x.
6
Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction.血管生成因子和子宫动脉多普勒对早发型与晚发型子痫前期及胎儿生长受限的预测价值。
Ultrasound Obstet Gynecol. 2008 Mar;31(3):303-9. doi: 10.1002/uog.5184.
7
Angiogenic and fibrinolytic factors in blood during the first half of pregnancy and adverse pregnancy outcomes.妊娠早期血中血管生成和纤溶因子与不良妊娠结局。
Obstet Gynecol. 2012 Jun;119(6):1190-200. doi: 10.1097/AOG.0b013e318256187f.
8
Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.妊娠早期血管生成因子失衡可预测狼疮和抗磷脂抗体患者的不良结局：PROMISSE研究结果
Am J Obstet Gynecol. 2016 Jan;214(1):108.e1-108.e14. doi: 10.1016/j.ajog.2015.09.066. Epub 2015 Sep 29.
9
The value of uterine artery Doppler ultrasound in the prediction of severe complications in a risk population.子宫动脉多普勒超声在预测高危人群严重并发症中的价值。
Arch Gynecol Obstet. 2005 Jan;271(1):53-8. doi: 10.1007/s00404-004-0648-4. Epub 2004 Jun 3.
10
Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks' gestation.孕11至14周时通过子宫动脉多普勒和妊娠相关血浆蛋白A筛查子痫前期和胎儿生长受限。
Ultrasound Obstet Gynecol. 2007 Feb;29(2):135-40. doi: 10.1002/uog.3881.

引用本文的文献

1
SHock-INduced Endotheliopathy (SHINE): A mechanistic justification for viscoelastography-guided resuscitation of traumatic and non-traumatic shock.休克诱导的内皮病变（SHINE）：创伤性和非创伤性休克粘弹性成像引导复苏的机制依据
Front Physiol. 2023 Feb 27;14:1094845. doi: 10.3389/fphys.2023.1094845. eCollection 2023.
2
Placenta Transcriptome Profiling in Intrauterine Growth Restriction (IUGR).宫内生长受限（IUGR）的胎盘转录组分析。
Int J Mol Sci. 2019 Mar 26;20(6):1510. doi: 10.3390/ijms20061510.
3
Correction: Tissue factor pathway inhibitor for prediction of placenta-mediated adverse pregnancy outcomes in high-risk women: AngioPred study.

本文引用的文献

1
TFPI resistance related to inherited or acquired protein S deficiency.与遗传性或获得性蛋白 S 缺乏相关的 TFPI 抵抗。
Thromb Res. 2012 Dec;130(6):925-8. doi: 10.1016/j.thromres.2012.07.025. Epub 2012 Oct 15.
2
Preeclampsia: the role of tissue factor and tissue factor pathway inhibitor.子痫前期：组织因子和组织因子途径抑制剂的作用。
J Thromb Thrombolysis. 2012 Jul;34(1):1-6. doi: 10.1007/s11239-012-0708-8.
3
Resistance to activated protein C is a risk factor for pregnancy-related venous thrombosis in the absence of the F5 rs6025 (factor V Leiden) polymorphism.
更正：组织因子途径抑制剂用于预测高危女性胎盘介导的不良妊娠结局：血管预测研究。
PLoS One. 2017 Jul 12;12(7):e0181474. doi: 10.1371/journal.pone.0181474. eCollection 2017.
对活化蛋白 C 的抵抗是妊娠相关静脉血栓形成的危险因素，而不存在 F5 rs6025（因子 V 莱顿）多态性。
Br J Haematol. 2011 Jul;154(2):241-7. doi: 10.1111/j.1365-2141.2011.08712.x. Epub 2011 May 12.
4
Increased risk of gestational vascular complications in women with low free tissue factor pathway inhibitor plasma levels out of pregnancy.妊娠期低游离组织因子途径抑制物血浆水平妇女发生妊娠血管并发症的风险增加。
Thromb Haemost. 2011 Jan;105(1):66-71. doi: 10.1160/TH10-06-0399. Epub 2010 Oct 26.
5
The relationship between plasma and placental tissue factor, and tissue factor pathway inhibitors in severe pre-eclampsia patients.严重子痫前期患者血浆与胎盘组织因子及组织因子途径抑制剂的关系。
Thromb Res. 2010 Jul;126(1):e41-5. doi: 10.1016/j.thromres.2010.02.012. Epub 2010 Mar 11.
6
Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma.遗传性和获得性蛋白 S 缺乏与血浆中 TFPI 水平降低有关。
J Thromb Haemost. 2010 Feb;8(2):294-300. doi: 10.1111/j.1538-7836.2009.03712.x. Epub 2009 Nov 30.
7
High tissue factor activity and low tissue factor pathway inhibitor concentrations in patients with preterm labor.早产患者的组织因子活性高且组织因子途径抑制物浓度低。
J Matern Fetal Neonatal Med. 2010 Jan;23(1):23-33. doi: 10.3109/14767050902994770.
8
Protein S as cofactor for TFPI.蛋白S作为组织因子途径抑制物的辅因子。
Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2015-20. doi: 10.1161/ATVBAHA.108.177436. Epub 2009 Aug 6.
9
The global impact of pre-eclampsia and eclampsia.子痫前期和子痫的全球影响。
Semin Perinatol. 2009 Jun;33(3):130-7. doi: 10.1053/j.semperi.2009.02.010.
10
Microparticles bearing tissue factor and tissue factor pathway inhibitor in gestational vascular complications.妊娠血管并发症中携带组织因子和组织因子途径抑制剂的微粒
J Thromb Haemost. 2009 Jun;7(6):1047-50. doi: 10.1111/j.1538-7836.2009.03342.x. Epub 2009 Mar 13.